Business
Xenetic Biosciences, Inc. to Present at BIO Investor Forum
Presentation with Live Audio Webcast on Wednesday, October 23rd at 2:45 PM PTFRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc.
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Presentation with Live Audio Webcast on Wednesday, October 23rd at 2:45 PM PTFRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell (\"CAR T\") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at BIO Investor Forum on Wednesday, October 23, 2019 at 2:45 PM PT in San Francisco, CA.As part of his presentation, Mr. Eisenberg will provide a Company overview and discuss the Company's novel CAR T platform technology, called \"XCART,\" a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. Xenetic is currently advancing the development program for XCART to confirm the positive preclinical results shown to date and to demonstrate a more attractive safety profile than existing therapies.In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.A live audio webcast of the presentation will be available on the IR Calendar in the Investors section of Xenetic's website (www.xeneticbio.com) or by accessing the conference website here. Within three days of the event, a webcast replay will be made available on the Company's website.About BIO Investor ForumNow in its 17th year, the BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables, therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings. For more information, please visit the conference website here.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's ma...